X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (152) 152
female (125) 125
male (116) 116
middle aged (93) 93
aged (81) 81
index medicus (81) 81
adult (63) 63
oncology (35) 35
treatment outcome (33) 33
italy - epidemiology (32) 32
aged, 80 and over (31) 31
risk factors (30) 30
italy (26) 26
cancer (25) 25
hematology (25) 25
retrospective studies (21) 21
care and treatment (20) 20
prognosis (20) 20
chemotherapy (19) 19
follow-up studies (19) 19
adolescent (18) 18
research (18) 18
survival (18) 18
disease-free survival (17) 17
prevalence (17) 17
analysis (16) 16
multiple myeloma - drug therapy (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
prospective studies (15) 15
transplantation (15) 15
cohort studies (14) 14
medicine, general & internal (14) 14
multiple myeloma - mortality (14) 14
public, environmental & occupational health (14) 14
survival analysis (14) 14
time factors (14) 14
surgery (13) 13
child (12) 12
elderly-patients (12) 12
epidemiology (12) 12
gastroenterology & hepatology (12) 12
mortality (12) 12
odds ratio (12) 12
recurrence (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
incidence (11) 11
kaplan-meier estimate (11) 11
population (11) 11
risk (11) 11
therapy (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
endocrinology & metabolism (10) 10
health aspects (10) 10
internal medicine (10) 10
logistic models (10) 10
management (10) 10
medicine & public health (10) 10
melphalan - administration & dosage (10) 10
oncology, experimental (10) 10
prednisone - administration & dosage (10) 10
proportional hazards models (10) 10
stem-cell transplantation (10) 10
thalidomide - administration & dosage (10) 10
trial (10) 10
disease (9) 9
health care sciences & services (9) 9
transplantation, autologous (9) 9
abridged index medicus (8) 8
age factors (8) 8
clinical neurology (8) 8
clinical trials (8) 8
comorbidity (8) 8
dexamethasone (8) 8
drug therapy (8) 8
hematology, oncology and palliative medicine (8) 8
outcomes (8) 8
practice guidelines as topic (8) 8
prednisone - adverse effects (8) 8
public health (8) 8
respiratory system (8) 8
risk assessment (8) 8
risk-factors (8) 8
stem cells (8) 8
surveys and questionnaires (8) 8
survival rate (8) 8
urology & nephrology (8) 8
asthma (7) 7
bortezomib (7) 7
carcinoma (7) 7
care (7) 7
cirrhosis (7) 7
cyclophosphamide - adverse effects (7) 7
diabetes (7) 7
diagnosis (7) 7
efficacy (7) 7
metabolic syndrome (7) 7
multiple myeloma (7) 7
multiple myeloma - therapy (7) 7
multivariate analysis (7) 7
neoplasm staging (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Recenti Progressi in Medicina, ISSN 0034-1193, 09/2014, Volume 105, Issue 9, pp. 315 - 316
Journal Article
Recenti progressi in medicina, ISSN 0034-1193, 09/2014, Volume 105, Issue 9, p. 315
A recent paper published in The BMJ has argued that the evidence-based medicine movement is now facing a serious crisis. In the authors' opinion, the first... 
Evidence-Based Medicine - trends | Delivery of Health Care - standards | Delivery of Health Care - methods | Patient Care - methods | Humans | Patient Care - standards | Practice Guidelines as Topic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2007, Volume 356, Issue 11, pp. 1110 - 1120
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 730 - 737
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 28, pp. 4459 - 4465
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 92, Issue 2, pp. 299 - 306
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 2/2014, Volume 116, Issue 3, pp. 533 - 541
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article